Tradipitant improves nausea, vomiting in gastroparesis

Tradipitant correlated with statistically and clinically meaningful improvements in nausea and decreased vomiting in patients with idiopathic or diabetic gastroparesis, according to results from Gastroenterology.“Tradipitant was demonstrated to be well-tolerated with an adverse event profile similar to placebo,” Jesse L. Carlin, PhD, lead clinical scientist from Vanda Pharmaceuticals Inc., the drug’s manufacturer, in Washington, D.C., and colleagues wrote. “The overall benefit risk profile, if confirmed, is likely to offer advantages over both approved and off labelRead More

Share on facebook
Share on twitter
Share on linkedin